Patents by Inventor Ervin H. Epstein, JR.

Ervin H. Epstein, JR. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Topical itraconazole formulations and uses thereof
    Patent number: 9072660
    Abstract: Methods of transdermally delivering a therapeutic amount of a triazole-triazolone compound are provided, e.g. for the prevention or treatment of basal cell carcinoma (BCC) in a subject. A therapeutic level of a triazole-triazolone compound such as itraconazole is delivered transdermally to a subject. Also provided are topical triazole-triazolone compositions that find use in practicing the subject methods.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: July 7, 2015
    Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, CHILDREN'S HOSPITAL & RESEARCH CENTER OAKLAND
    Inventors: Ervin H. Epstein, Jr., Jean Tang, Philip A. Beachy, Jayakumar Rajadas, James Kim
  • Topical Itraconazole Formulations and Uses Thereof
    Publication number: 20130109700
    Abstract: Methods of transdermally delivering a therapeutic amount of a triazole-triazolone compound are provided, e.g. for the prevention or treatment of basal cell carcinoma (BCC) in a subject. A therapeutic level of a triazole-triazolone compound such as itraconazole is delivered transdermally to a subject. Also provided are topical triazole-triazolone compositions that find use in practicing the subject methods.
    Type: Application
    Filed: September 7, 2012
    Publication date: May 2, 2013
    Inventors: Ervin H. Epstein, JR., Jean Tang, Philip A. Beachy, Jayakumar Rajadas, James Kim
  • Transgenic Animal Model of Cancer and Methods of Use
    Publication number: 20110030071
    Abstract: The invention features a transgenic mouse model of cancer, exemplified by basal cell carcinoma, which finds use in identification of anti-cancer drugs. The transgenic mouse is characterized by a heterozygous defect in a Patch gene (Ptch+/?) and an inducible suppression of functional p53.
    Type: Application
    Filed: April 9, 2009
    Publication date: February 3, 2011
    Inventors: Ervin H. Epstein, JR., Po-Lin So, Jean Tang